February 26, 2021

Canagliflozin (TA-7284) has been approved in Taiwan
For Diabetic Nephropathy
Mitsubishi Tanabe Pharma Corporation (MTPC) (Head Office: Osaka; President &Representative Director, CEO: Hiroaki Ueno), announced today that Tai Tien
Pharmaceuticals Co., Ltd. (Tai Tien) (Head Office: Taipei, Taiwan; General Manager
Tony Chu), which is a consolidated subsidiary of MTPC obtained the regulatory
approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU®
Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA onFebruary 1, 2021.
Diabetic nephropathy, which is one of the three major complications of diabetes
mellitus, is a disease that causes decreased renal function due to vascular disorderof the kidney and ultimately requires dialysis therapy. As the number of patientswith diabetes increases, so does the number of patients with this disease, which isthe biggest reason for introducing dialysis therapy. The development of therapies toimprove this situation is an important issue not only from the viewpoint of patients'
QOL but also from the viewpoint of health economics.
CANAGLU is a treatment agent for type 2 diabetes mellitus discovered by MTPC.
CANAGLU was approved in March 2017 in Taiwan and has been marketed since
March 2018.
For the indication of diabetic nephropathy, CANAGLU has already been approved in
more than 49 countries worldwide by a licensee, Janssen Pharmaceuticals, Inc., andits affiliates, under the brand name INVOKANA.
In Japan, MTPC is currently conducting a phase 3 clinical study.
Tai Tien, which was established in 1987, has contributed to the treatment of patientswith type 2 diabetes by supplying numerous products for lifestyle-related diseases.
In Taiwan, the incidence and prevalence of ESRD are among the highest in the world*,and dialysis costs have a significant impact on healthcare finances. In addition, there
are more than 2.2 million patients with diabetes mellitus, which has been increasing
in recent years*, making diabetic nephropathy an issue that needs to be resolved assoon as possible.

1/2

By providing new options for the treatment of diabetes to a growing number ofpatients in the world, MTPC group show its continued resolve to improve their qualityof life (QOL).
*2019 Taiwan Clinical Practice Guideline for Diabetic Kidney

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119

<Reference>■canagliflozin (Japan names: CANAGLU® Tablets 100mg)
Canagliflozin (INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) is an
SGLT2 inhibitor that originated in Japan. It is a treatment for type 2 diabetes mellitus
which was discovered by Mitsubishi Tanabe Pharma and has its research roots in T1095, the world’s first orally bioavailable sodium glucose co-transporter inhibitor.
CANAGLU® inhibits SGLT2, a transporter involved in the reabsorption of glucose in
the renal tubules of the kidneys, suppresses the reabsorption of glucose, promotes
the excretion of excessive glucose into the urine, and as a result, lowers the blood
glucose level. Canagliflozin was approved in Japan, July 2014 followed by Taiwan inMarch 2017.

■Tai Tien Pharmaceuticals Co., Ltd (Tai Tien)
Tai Tien Pharmaceuticals, which was established in Taipei in 1987, has marketedsuch products as HERBESSER®, CONCOR® (Japan name: MAINTATE®), andLIVALO®. With the launch of CANAGLU®, Tai Tien is contributing to the treatmentof patients with type 2 diabetes in Taiwan by leveraging the foundation of its core
therapeutic area for lifestyle-related diseases.

2/2